Table V.

Relationship between KIF3A expression and clinicopathological parameters in the140 cases by intensity of positive.

	Intensity of positive
Item	0	1	2	3	No.	P-value
Age						0.728
≤53	2	15	31	32	80
>53	2	7	25	26	60
Pathology grade						0.000b
I	1	7	4	0	12
I–II	0	2	12	8	22
II	2	13	37	43	95
III	0	0	2	5	7
ER
Positive	2	12	35	39	88	0.463
Negative	1	10	16	15	42
PR
Positive	2	10	32	34	78	0.475
Negative	0	11	20	20	51
AR
Positive	4	12	36	48	100	0.021a
Negative	0	10	20	10	40
HER2
Positive	1	5	13	23	42	0.211
Negative	2	17	38	32	89
Lymph node
metastasis
TnN0	4	4	23	37	86	0.013a
TnNn	0	18	21	16	46
P53
Positive	1	15	33	37	86	0.495
Negative	2	7	21	16	46
Ki-67
−	1	6	11	6	24	0.320
+	2	11	32	30	75
++	0	4	7	11	22
+++	0	1	3	6	10
Ck56
Positive	0	2	10	7	19	0.757
Negative	3	20	43	46	112
EGFR
Positive	4	19	43	36	102	0.023a
Negative	0	3	13	21	37
TN
TNBC	0	6	5	7	18	0.046
NTNBC	6	23	43	31	103

^aP<0.05

^bP<0.001. KIF3A, Kinesin Family Member 3A; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.